Prognostic biomarkers of IFNb therapy in multiple sclerosis patients

• Published in: Multiple sclerosis Vol. 21; no. 7; pp. 894 - 904
• Main Authors: Baranzini, Sergio E, Madireddy, Lohith R, Cromer, Anne, D’Antonio, Mauro, Lehr, Lorenz, Beelke, Manolo, Farmer, Pierre, Battaglini, Marco, Caillier, Stacy J, Stromillo, Maria L, De Stefano, Nicola, Monnet, Emmanuel, Cree, Bruce AC
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.06.2015; Sage Publications Ltd
• Subjects: Adult; Area Under Curve; Biomarkers - analysis; Caspase 2 - genetics; Cysteine Endopeptidases - genetics; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunologic Factors - therapeutic use; Interferon Regulatory Factors - genetics; Interferon-beta - therapeutic use; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - genetics; Polymerase Chain Reaction; Prognosis; ROC Curve; Sensitivity and Specificity; Treatment Outcome; interferon beta; prognostic; Biomarker; RNA; multiple sclerosis; bioinformatics

Background: Interferon beta (IFNb) reduces relapse frequency and disability progression in patients with multiple sclerosis (MS). Objectives: Early identification of prognostic biomarkers of IFNb-treated patients will allow more effective management of MS. Methods: The IMPROVE study evaluated subcut...